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Purpose of the study
Development and post-marketing data suggest that
some licensed ARV doses could be reduced. We
assessed the pharmacokinetics (PK) of lopinavir/ritona-
vir (LPV/r) following the administration of 3 different
doses to HIV negative volunteers as a preliminary to the
design of clinical trials to examine the safety and effi-
cacy of novel dose regimens in HIV positive subjects.
Methods
Following written consent, male and female volunteers
were administered LPV/r 400/100 (2 LPV/r Meltrex
200/50 tablets; regimen 1), 200/150 (1 Meltrex tablet, 1
100mg ritonavir capsule; regimen 2), and 200/50 (1 Mel-
trex tablet; regimen 3) mg twice daily (BID) for 7 days
sequentially. Each 7-day phase was separated by a 7-day
wash-out period and LPV/r steady-state PK was assessed
over 12 hours on the last day of each dosing phase (days
7, 21 and 35). PK parameters were compared using
Phase 1 as reference by determining geometric mean
ratios (GMR) and 90% confidence intervals (CI). Safety
and tolerability were assessed throughout the study
period.
Summary of results
Twenty-two subjects (8 female) were enrolled and com-
pleted the study. GM PK parameters (90% CI) of the 3
doses are shown in Table 1.
LPV PK parameters in regimens 2 and 3 were lower:
GMR (90%CI) AUC 0.74 (0.65-0.84) and 0.45 (0.40-
0.51); Cmax 0.75 (0.66-0.85) and 0.54 (0.40-0.60); C12h
0.74 (0.62-0.89) and 0.30 (0.25-0.36). All subjects in regi-
mens 1 and 2 had LPV concentrations above the sug-
gested minimum effective concentration (MEC) of
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Table 1
PK parameter 400/100 BID 200/150 BID 200/50 BID
regimen 1 regimen 2 regimen 3
Lopinavir
AUC0-12 (ng.h/mL) 99599 (87180-113787) 73603 (65121-83191) 45146 (39251-51927)
Cmax (ng/mL) 11965 (10400-13766) 8939 (8047-9930) 6404 (5648-7262)
C12h (ng/mL) 5776 (4884-6831) 4293 (3603-5115) 1749 (1419-2156)
Ritonavir
AUC0-12 (ng.h/mL) 4664 (3808-5664) 10462 (8972-12200) 1625 (1390-1899)
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concentrations. No serious adverse events were observed
and as expected mild/moderate diarrhoea was the most
common adverse effect.
Conclusions
These PK data indicate that therapeutically relevant
plasma concentrations of LPV can be achieved with
lower administered doses and support further explora-
tion of these lower LPV doses in properly designed ran-
domised clinical trials. Preservation of therapeutically
relevant LPV doses requires administration of higher
doses of ritonavir. A new dose of LPV/r could lower
cost and improve access in developing countries.
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